A new analysis of transurethral microwave thermotherapy (TUMT) treatments using the Prostatron device and Prostasoft v2.5 software reveals that while the procedure significantly improves symptoms associated with benign prostatic hyperplasia (BPH), it does not effectively alleviate urinary obstruction—the underlying cause of many BPH-related complications.
Benign prostatic hyperplasia, a common condition in aging men, involves the non-cancerous enlargement of the prostate gland, which can lead to lower urinary tract symptoms such as frequent urination, urgency, weak stream, and incomplete bladder emptying. TUMT is a minimally invasive technique designed to address these concerns by using heat generated by microwaves to shrink excess prostate tissue.
The review of patient outcomes highlighted that symptom alleviation could give a false sense of restored function. Despite clinical improvement in discomfort and frequency of urination, objective measures showed persistent blockage or obstruction in the urinary tract. This suggests that while TUMT can improve quality of life in the short term, it may not prevent the long-term complications associated with untreated obstruction.
Additionally, the study found that patients treated using this thermotherapy approach—and specifically managed with Prostasoft v2.5—were at risk for ejaculatory dysfunction, a side effect that should be clearly discussed with patients prior to treatment. Ejaculatory dysfunction may include reduced or absent semen during orgasm, which can be distressing and affect quality of life.
The findings underscore the importance of informed consent and comprehensive patient counseling. Physicians are encouraged to set realistic expectations and carefully consider the suitability of TUMT in the treatment plan for patients with BPH, especially for those who prioritize preservation of sexual function or are at risk of complications related to unaddressed urinary obstruction.
Source: https:// – Courtesy of the original publisher.
